Answers are grounded in this paper and cite their sources.
Lenalidomide has hematologic activity in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy.
No takes yet. Share an insight, caveat, or question.
List et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: